Monte Rosa Therapeutics (GLUE) said Wednesday that data from a preclinical trial of its drug MRT-9643 as a potential treatment for HR-positive/HER2-negative breast cancer has superior selectivity relative to other clinical-stage cyclin-dependent kinase 2 inhibitors and induced robust downstream CDK2 pathway suppression.

MRT-9643 drove deep tumor regression in preclinical cellular models of HR-positive/HER2-negative breast cancer when combined with current standard of care therapies, the company said.

"Our results demonstrate that MRT-9643 is a highly selective oral CDK2 degrader that could potentially avoid many of the dose-limiting toxicities associated with less selective CDK2 inhibitors," Chief Scientific Officer Sharon Townson said.